

A REVIEW OF SUSTAINABLE STRATEGIES FOR ENHANCING PHARMACEUTICAL SUPPLY CHAIN RESILIENCE

Aafiya Jahan M¹, Vishal Gupta², H S Thrisha³, T M Pramod Kumar^{4*}

^{1,3,4}Department of Pharmaceutics, JSS Academy of Higher Education and Research, Mysuru, Karnataka

²Department of Pharmacognosy, JSS Academy of Higher Education and Research, Mysuru, Karnataka

Corresponding Author: T M Pramod Kumar

DOI: [https://doi.org/10.63001/tbs.2026.v21.i02.S.I\(2\).pp41-47](https://doi.org/10.63001/tbs.2026.v21.i02.S.I(2).pp41-47)

KEYWORDS

Supply chain management, Pharmaceutical Supply chain, economic impact, Resilience, Just in time

Received on:

10-02-2026

Accepted on:

08-03-2026

Published on:

05-04-2026

Abstract

The pharmaceutical supply chain is a critical component of global healthcare infrastructure, ensuring the continuous availability of safe and effective medicines. However, increasing globalisation, regulatory complexities and disruptions such as pandemics have exposed its vulnerability. This review explores sustainable strategies that enhance the resilience of pharmaceutical supply chains by integrating environmental, economic and social dimensions of sustainability. Key approaches include digital transformation through technologies like artificial intelligence, blockchain and the Internet of Things (IoT) to improve transparency, traceability and decision-making. Additional strategies encompass predictive analytics for disruption management, ethical sourcing, supplier and route diversification, inventory optimisation and green logistics. Emphasis is placed on the adoption of circular economy principles, local sourcing and collaboration among stakeholders to ensure long-term stability and adaptability. The study also highlights the importance of regulatory compliance, risk assessment frameworks and capacity-building initiatives for workforce development. By embedding sustainability into core operations, pharmaceutical organisations can achieve operational efficiency, environmental stewardship and social responsibility while strengthening preparedness against future disruptions.

1. INTRODUCTION

The accelerating pace of technological innovation, changing market trends and evolving consumer behaviours have profoundly reshaped the functioning of modern enterprises. In the context of a highly interconnected global economy, organisations no longer operate as independent units but as integral components of complex collaborative networks working toward shared goals. To remain competitive and stable within this dynamic environment, the establishment of a robust and adaptive supply chain has become essential¹⁻³. However, as supply chains have grown increasingly sophisticated driven by shorter product lifecycles, market volatility and unexpected external pressures they have also become more prone to risks and disruptions⁴.

Various industries frequently encounter interruptions triggered by natural calamities, geopolitical instability, cyber incidents, pandemics and other crises. To address these vulnerabilities, the concept of supply chain resilience has gained prominence. It

represents an organisations capacity to predict, endure, adapt to and recover from adverse events while maintaining business continuity⁵. A resilient supply chain not only safeguards the steady movement of goods and services but also preserves financial stability and enhances long-term competitiveness. Beyond mere recovery, resilience encompasses flexibility, adaptability and sustainability qualities that enable firms to thrive under uncertainty and ensure enduring operational stability^{1,3}.

Over the past few decades, the importance of resilience within supply chain management has significantly increased, with organisations implementing proactive strategies to foresee and mitigate potential disruptions, alongside reactive measures to enable swift recovery. Balancing these approaches is vital for sustaining efficiency, cost-effectiveness and preparedness⁶⁻⁷. Within this broader landscape, the pharmaceutical supply chain holds particular importance due to its direct link to patient well-being and public health outcomes. This intricate network spans multiple stages, including the procurement of raw materials,

drug production, packaging, distribution and final delivery to healthcare providers⁸.

Effective collaboration among manufacturers, distributors, suppliers, healthcare professionals and regulatory agencies is essential to ensure the quality, safety and availability of medicinal products. The pharmaceutical supply chain's resilience is crucial to guaranteeing the uninterrupted supply of life-saving medicines, especially during emergencies when demand surges unexpectedly⁹. Events such as the COVID-19 pandemic have exposed critical vulnerabilities, including drug shortages and distribution delays that compromise healthcare delivery¹². The globalisation of production and supply has further amplified these risks by creating dependencies across diverse international partners. While the adoption of digital technologies such as automation, data analytics and real-time tracking systems has improved visibility and operational efficiency, significant challenges persist due to logistical constraints, complex regulations and limited coordination among stakeholders^{10,11}. Given its vital role in healthcare systems, establishing sustainable and resilient pharmaceutical supply chains is now a global priority. Sustainability in this setting extends beyond environmental conservation to encompass economic viability and social accountability. Incorporating sustainable practices such as eco-efficient logistics, circular resource utilization, responsible sourcing and digital transformation can enhance resilience and support continuous operations.

This review focuses on sustainable strategies that strengthen the resilience of pharmaceutical supply chains by fostering adaptability, flexibility and long-term stability.

STRATEGIES:

Sustainable Pharmacy Supply Chain Management (SPSCM) plays a vital role in ensuring the continuous availability, affordability and quality of pharmaceutical products while reducing environmental impact.

Digital Transformation and Supply Chain:

The pharmaceutical supply chain is entering a new era of innovation through the adoption of advanced digital technologies, collectively known as Supply Chain 4.0. The integration of the Internet of Things (IoT), artificial intelligence (AI) and machine learning (ML) is fundamentally transforming the management and coordination of supply chain operations. IoT-based systems enable the continuous collection of real-time information regarding the location, condition and movement of pharmaceutical products across the supply network. This enhanced visibility ensures improved monitoring, greater accuracy and proactive risk management. In parallel, AI and ML applications analyze large volumes of operational data to streamline workflows, identify inefficiencies and forecast potential disruptions, thereby facilitating data-driven and strategic decision-making. By merging automation with predictive analytics, Supply Chain 4.0 fosters adaptability and responsiveness, enabling pharmaceutical organisations to effectively respond to market fluctuations, regulatory shifts and unexpected challenges. This digital evolution not only strengthens supply chain resilience but also advances sustainability, operational efficiency and patient safety within the pharmaceutical sector¹³.

Predictive Analytics for Proactive Disruption Management:

Predictive analytics is driven by artificial intelligence (AI) and machine learning (ML), has emerged as a critical component in strengthening proactive disruption management within the pharmaceutical supply chain. By examining historical data and uncovering hidden patterns, predictive models can anticipate potential disturbances such as transportation delays, equipment malfunctions, or sudden fluctuations in demand well before they occur. This predictive capability enables organisations to implement pre-emptive measures, including optimizing

inventory levels, rerouting shipments, or activating contingency strategies to mitigate risks and maintain operational continuity. As predictive analytics technologies advance, they are becoming indispensable for enhancing supply chain resilience, improving decision-making accuracy and ensuring uninterrupted access to essential medicines even amid unforeseen challenges¹⁴.

Sustainability into Supply Chain Resilience Strategies:

Sustainability has become an integral element of modern supply chain resilience, particularly within the pharmaceutical industry. Embedding sustainable practices into supply chain operations not only supports environmental protection but also strengthens long-term operational stability and business continuity. Key sustainability initiatives include waste reduction, carbon footprint minimization and efficient resource utilization. For instance, the use of eco-friendly packaging materials, energy-efficient manufacturing systems and green logistics can help reduce reliance on finite resources while simultaneously lowering operational expenses. Moreover, organisations that embrace sustainability are better positioned to comply with evolving environmental regulations and respond to the growing consumer and institutional demand for environmentally responsible products. These efforts collectively enhance both the resilience and reputation of pharmaceutical supply chains¹⁵.

Ethical Sourcing Integrating:

Ethical sourcing plays a crucial role in ensuring that every material and component within the pharmaceutical supply chain is obtained through environmentally responsible and socially conscious practices. It emphasizes compliance with fair labor standards, maintenance of safe workplace conditions and the sustainable utilization of natural resources. Upholding ethical sourcing principles not only reinforces the credibility and accountability of pharmaceutical organisations but also strengthens their long-term resilience. By preventing challenges linked to unethical behavior such as worker exploitation, environmental harm and reputational crises this approach enhances stability and trust throughout the supply network. Companies that prioritize transparent procurement systems and ethical supplier partnerships are better equipped to establish reliable relationships with regulators, suppliers and other key stakeholders. Consequently, ethical sourcing serves as a foundation for developing a sustainable, adaptable and resilient pharmaceutical supply chain that can effectively endure future disruptions and global uncertainties¹⁶.

Supplier and Route Diversification:

Diversifying suppliers and transportation routes is a critical strategy for reducing vulnerabilities within the pharmaceutical supply chain. By sourcing raw materials and components from multiple suppliers and employing various transportation channels, organisations can minimize dependence on a single source or route. This approach mitigates the impact of potential disruptions arising from supplier failures, logistical bottlenecks, or geopolitical instabilities¹⁷. Supplier and route diversification enhances the continuity of supply, ensuring that manufacturing and distribution processes remain uninterrupted even during unforeseen crises. Supplier diversification is recognized as one of the most effective strategies for strengthening the resilience of pharmaceutical supply chains. This approach involves expanding and diversifying supplier networks to reduce dependency on single sources for essential materials and components. A vital element of this strategy is geographical dispersion, which helps minimize the risks associated with regional disruptions such as political instability, natural disasters, or public health crises. In recent years, many organisations have adopted strategies like the "China plus one" or "China plus many" models to avoid over-reliance on a single region, thereby ensuring a more balanced and resilient sourcing structure. Another essential component is multi-sourcing, which entails approving multiple suppliers for the same active

pharmaceutical ingredients or raw materials. This ensures continuity of supply even when one source experiences production delays, quality issues, or regulatory challenges¹⁸. Despite its advantages, supplier diversification also presents certain challenges, including increased operational complexity, higher logistical and administrative costs and compliance difficulties due to rigorous regulatory and supplier qualification requirements. Addressing these trade-offs demands careful strategic planning, risk assessment and strong supplier relationship management. Research and practical experience indicate that companies implementing supplier diversification strategies have achieved significant reductions between 30% and 50% in supply chain disruptions. This demonstrates the strategy's effectiveness in improving overall resilience and ensuring uninterrupted access to essential pharmaceutical products¹⁹⁻²⁰.

Inventory Optimization Effective:

Inventory optimization focuses on maintaining the right balance between product availability and cost efficiency. It involves aligning inventory levels with actual demand to prevent both overstocking, which leads to increased carrying costs and stockouts, which can disrupt production and customer satisfaction. Advanced techniques such as just-in-time (JIT) inventory management, safety stock optimization and demand forecasting enable organisations to improve turnover rates, manage excess inventory and respond quickly to fluctuations in demand or supply²¹. Maintaining higher inventory levels and safety stock has become one of the most commonly adopted strategies to strengthen the resilience of pharmaceutical supply chains. This method involves storing larger quantities of essential drugs, raw materials and intermediates to safeguard against unexpected disruptions in supply or sudden surges in demand. A key element of this approach is the strategic stockpiling of critical medicines and materials, which can be implemented both at the organisational level and through national initiatives designed to ensure the availability of essential products during emergencies¹⁷. A more advanced development within this strategy is dynamic inventory management, which adjusts stock levels in response to real-time assessments of supply chain risks, market fluctuations and the importance of specific drugs. This enables companies to maintain optimal inventory levels while responding swiftly to emerging challenges. Although increasing inventory can effectively cushion short-term disruptions, it also presents notable challenges, including higher storage and handling costs, risks of product expiration and operational inefficiencies. For pharmaceuticals with limited shelf lives or requiring specialized storage conditions, this approach may have limited applicability. Nevertheless, evidence suggests that companies implementing enhanced inventory and safety stock strategies have experienced significant reductions estimated between 40% and 60% in stockouts of critical drugs. However, these benefits must be balanced against the financial and logistical implications to ensure that inventory management remains both resilient and sustainable in the long term²¹.

Technology Adoption:

The adoption of digital technologies is transforming supply chain management by enhancing visibility, traceability and operational efficiency. Tools such as real-time tracking systems, predictive analytics and cloud-based platforms enable continuous monitoring of supply chain activities, early detection of potential disruptions and informed, timely decision-making. Through the integration of these technologies, pharmaceutical companies gain greater agility and responsiveness, allowing them to quickly adapt to changing conditions and maintain continuity. Technological innovation thus plays a pivotal role in reinforcing supply chain resilience, improving transparency and ensuring seamless coordination among all stakeholders. The integration of advanced technologies has become a crucial strategy for strengthening the resilience of pharmaceutical supply chains. This approach leverages innovative digital tools to enhance visibility, traceability and data-driven decision-

making throughout the supply network. Blockchain technology has emerged as a transformative solution for ensuring transparency and integrity across the pharmaceutical supply chain. By providing secure and tamper-proof records of transactions, blockchain helps prevent counterfeit drugs from entering the market and enhances confidence in the authenticity of products. Pilot studies have demonstrated that the use of blockchain can significantly reduce the circulation of counterfeit drugs, reinforcing the reliability of pharmaceutical distribution systems. Artificial Intelligence (AI) and Machine Learning (ML) are increasingly being used to improve demand forecasting, risk prediction and supply planning. These technologies analyze vast amounts of data to identify trends, anticipate disruptions and enable more precise forecasting. In several cases, AI-driven models have notably improved forecast accuracy, supporting better inventory management and production scheduling. Meanwhile, the Internet of Things (IoT) is revolutionizing real-time monitoring across supply chain operations. IoT-enabled sensors and devices track inventory levels, transportation conditions and equipment performance, providing critical insights for proactive issue resolution and quality assurance. Despite these benefits, the widespread adoption of advanced technologies faces several challenges, including high implementation costs, limited technical expertise and concerns about data security and privacy. Additionally, integrating these systems with existing infrastructure remains a major hurdle for many organisations. Nonetheless, as digital transformation continues to advance, the strategic adoption of these technologies will play a central role in building a more agile, transparent and resilient pharmaceutical supply chain²³⁻²⁴.

Flexibility and Agility Building:

Flexibility and agility into supply chain operations allows organisations to rapidly adjust to evolving market conditions, environmental shifts and customer requirements. Companies that embrace flexible manufacturing systems, agile distribution networks and responsive logistics frameworks can swiftly modify production schedules, reroute shipments and reallocate resources when disruptions occur. This adaptability not only minimizes downtime and losses during crises but also enhances overall competitiveness²⁵.

Forecasting and Demand Planning:

Enhancing forecasting and demand planning has emerged as a critical strategy for building resilience within the pharmaceutical supply chain. This approach focuses on developing accurate and timely predictions of drug demand while identifying potential disruptions that could affect supply continuity. One of the most effective methods for implementing this strategy is collaborative forecasting with healthcare providers. By integrating real-time data from hospitals, pharmacies and other healthcare institutions, pharmaceutical companies gain a clearer understanding of consumption trends and patient needs. Such data-driven collaboration has been shown to significantly reduce forecasting errors, leading to improved production planning and distribution efficiency. Furthermore, incorporating external data sources including epidemiological patterns, weather variations and socioeconomic indicators enables the creation of more precise and context-aware demand models. The use of advanced analytics and machine learning tools helps process large, complex datasets to generate accurate, adaptive forecasts. In addition, organisations are increasingly employing scenario planning and simulation models to anticipate potential disruptions. These approaches allow companies to evaluate their supply chain performance under various hypothetical conditions and design robust contingency plans accordingly. Evidence indicates that improved forecasting and demand planning can lead to notable reductions approximately 15-25% in stockouts and 10-20% in excess inventory costs. However, successful implementation still depends on overcoming key challenges such as data quality issues, system integration difficulties and the inherent uncertainty in pharmaceutical demand. Addressing these

limitations through digital innovation and cross-sector collaboration can significantly strengthen supply chain predictability, responsiveness and long-term resilience^{26-27,24}.

Vertical Integration:

Vertical integration is a strategic approach in which pharmaceutical companies expand their control over multiple stages of the supply chain to improve operational efficiency and reduce external dependencies. This integration can occur in two primary forms: backward integration and forward integration. In backward integration, companies secure the supply of essential raw materials by acquiring or partnering with suppliers. This strategy minimizes reliance on external vendors and helps mitigate risks associated with raw material shortages, price volatility, or supply disruptions. By ensuring a stable input flow, organisations enhance both the reliability and cost-efficiency of their production processes. Forward integration, on the other hand, involves gaining control over downstream distribution channels, enabling companies to oversee the entire process from production to final product delivery. This direct involvement improves quality control, strengthens coordination with distributors and retailers and enhances responsiveness to market demand. Through vertical integration, pharmaceutical firms can achieve greater transparency, streamline operations and enhance supply chain resilience by reducing exposure to external uncertainties²⁸⁻²⁹.

Reshoring and Nearshoring:

Reshoring and nearshoring have emerged as significant strategies for building resilient and sustainable pharmaceutical supply chains. These approaches involve relocating manufacturing operations closer to the target markets either within the company's home country (reshoring) or in nearby regions (nearshoring). This shift addresses vulnerabilities exposed by recent global disruptions, such as the COVID-19 pandemic, which highlighted the risks of overdependence on distant manufacturing hubs. By bringing production closer to end markets, companies can reduce lead times, improve supply chain visibility and respond more swiftly to fluctuations in demand. Moreover, many governments are now offering policy incentives and financial support to encourage domestic production of essential medicines³⁰. This localization of manufacturing not only strengthens national healthcare security but also supports sustainable employment and economic stability. By relocating production and sourcing activities closer to end markets, companies can significantly reduce transportation costs and lead times while improving supply chain responsiveness. Nearshoring also minimizes the risk of disruptions caused by port congestion, customs delays, or geopolitical uncertainties associated with long-distance international shipping. The reduced travel distance enhances reliability in product delivery and supports better coordination between manufacturers and distributors. Moreover, this strategy fosters stronger regional partnerships, allows for greater supply chain visibility and contributes to sustainability by lowering carbon emissions from transportation³¹.

Risk Management and Contingency Planning:

Risk management and contingency planning form a cornerstone of strategies aimed at strengthening pharmaceutical supply chain resilience. This approach involves the establishment of comprehensive frameworks designed to identify, assess and mitigate potential risks that may disrupt the flow of materials or finished products. Organisations utilize risk assessment tools to pinpoint vulnerabilities within their supply networks and implement corresponding mitigation measures to minimize their impact³². Key methodologies such as scenario planning and stress testing are employed to simulate different disruption scenarios ranging from natural disasters and geopolitical conflicts to pandemics and market volatility. These simulations enable companies to evaluate their supply chain responsiveness under various stress conditions and to formulate contingency

plans that ensure continuity of operations when disruptions occur. By having well-defined recovery strategies, companies can respond rapidly, minimize losses and restore normal functioning with minimal downtime³³.

Collaboration and Information Sharing:

Collaboration and information sharing represent another vital dimension of supply chain resilience. This strategy emphasizes coordinated efforts among stakeholders, including manufacturers, distributors, healthcare providers and regulatory agencies, to foster transparency, agility and collective problem-solving. Enhanced communication across the supply network allows for real-time visibility into inventory levels, production schedules and logistics operations, thereby supporting better planning and faster decision-making³⁴. A particularly effective model within this strategy is the development of public-private partnerships (PPPs). These collaborations enable resource pooling and joint initiatives that enhance preparedness and response to large-scale disruptions³⁵.

Local sourcing:

Local sourcing focuses on obtaining raw materials, active pharmaceutical ingredients (APIs) and essential components from nearby or regional suppliers to reduce reliance on global supply chains, minimize exposure to international sanctions and shorten delivery times. This strategy enhances supply chain resilience, lowers transportation costs, decreases carbon emissions and supports regional economic development. To implement this approach effectively, pharmaceutical companies should conduct a comprehensive feasibility study to identify capable local suppliers who meet quality, safety and regulatory standards. Building long-term partnerships through supplier development programs, joint ventures and capacity-building initiatives ensures consistency, quality and reliability. Additionally, investing in supplier training, establishing transparent communication systems and adopting digital procurement tools can strengthen coordination and performance monitoring. Collaborating with government bodies and industry associations can further promote local production through policy support and incentives³⁶.

Robust risk assessment:

Robust risk assessment involves systematically identifying, analyzing and mitigating potential vulnerabilities within the pharmaceutical supply chain, such as geopolitical tensions, natural disasters, economic fluctuations and regulatory shifts. This proactive approach enables companies to anticipate disruptions and maintain continuity in the delivery of critical medicines. Implementing this strategy requires the development of a comprehensive risk assessment framework that utilizes quantitative and qualitative scoring systems to evaluate the severity and likelihood of various risk factors. Regular reviews and updates should be conducted to ensure the framework remains aligned with evolving global conditions and market dynamics. Integrating advanced analytical tools, such as predictive modeling and scenario analysis, can enhance the accuracy of risk identification and preparedness planning. Additionally, fostering cross-functional collaboration between procurement, logistics and regulatory teams helps ensure that mitigation measures are well-coordinated and actionable³⁷.

Transportation routes:

Developing and maintaining alternative transportation routes is a key strategy to ensure the uninterrupted and timely delivery of pharmaceutical products in the event that traditional logistics pathways are disrupted. This approach involves proactively identifying and mapping out multiple transportation options such as air, sea and land routes to provide flexibility and minimize delays during emergencies or unforeseen disruptions like natural disasters, political unrest, or port closures. Implementation requires close collaboration with logistics providers, freight forwarders and supply chain partners to design and validate

contingency plans that can be swiftly activated when needed. Advanced logistics planning tools and real-time tracking systems can be employed to monitor route performance, assess risks and optimize delivery schedules. By diversifying transportation methods and building resilient logistics networks, pharmaceutical organisations can enhance supply chain agility, reduce dependency on single routes and ensure consistent access to essential medicines even under adverse conditions³⁸.

Collaboration and strategic partnerships:

Establishing collaboration and strategic partnerships is essential for strengthening resilience and efficiency within the pharmaceutical supply chain. This strategy focuses on building alliances with other pharmaceutical companies, healthcare providers, government agencies and research institutions to share resources, expertise and operational capabilities. Through such cooperation, organisations can jointly address challenges such as supply disruptions, regulatory compliance and capacity limitations. Implementation involves active participation in industry associations, professional networks and collaborative forums that facilitate information exchange and relationship building. Additionally, forming joint ventures or partnership agreements allows companies to pool financial and technological resources, share risks and leverage each other's strengths in areas like manufacturing, distribution and innovation. These collaborative efforts not only enhance the agility and responsiveness of the supply chain but also promote the development of standardized best practices and shared frameworks for sustainable growth and crisis management³⁵⁻³⁶.

Regulatory knowledge and adaptability:

Regulatory knowledge and adaptability are vital for maintaining compliance and operational continuity within the pharmaceutical supply chain. This strategy emphasizes the importance of staying informed about evolving regulations, trade policies and potential sanctions that may impact sourcing, manufacturing, or distribution processes. Effective implementation involves establishing a structured framework for continuous regulatory monitoring and compliance management. Organisations should regularly train employees on updated legal requirements, quality standards and industry guidelines to ensure adherence across all operational levels. Maintaining a centralized and up-to-date database of relevant national and international regulations facilitates quick reference and informed decision-making. Additionally, engaging legal and regulatory experts helps organisations navigate complex compliance landscapes, anticipate potential risks and adapt business practices proactively³⁵.

Operational marketing and sales strategy:

An effective operational marketing and sales strategy is vital for driving growth, competitiveness and profitability within the pharmaceutical industry. According to a report by the U.S. Bureau of Statistics (2011), pharmaceutical drug consumption in the U.S. accounted for up to 37% of the market value, highlighting the sector's significant economic contribution. A well-structured marketing and sales framework aligns business strategies with market needs, emphasizing value creation and customer engagement. Strategic sourcing has evolved as a critical component of operational efficiency, shifting focus from merely assessing purchase prices to evaluating the total cost of ownership (TCO) of a product or service. This comprehensive approach encourages procurement teams to look beyond initial costs and consider long-term implications such as operating expenses, training, warehousing, environmental impact, quality assurance and transportation. Modern procurement practices, therefore, move away from traditional multi-bid evaluations based solely on price and instead incorporate a holistic understanding of cost, value and sustainability³⁹.

Partnerships and mergers:

Partnerships and mergers play a pivotal role in driving growth and competitiveness within the pharmaceutical industry. Strategic collaborations and outsourcing have become integral to achieving operational efficiency, innovation and market expansion. According to Management Centre Europe, mergers and acquisitions are projected to contribute over 50% of the pharmaceutical sector's future growth in global markets. Through such alliances, companies can pool resources, share expertise and strengthen their market presence while accelerating research and development efforts. Effective mergers not only enhance economies of scale but also facilitate entry into new therapeutic areas and geographic regions. However, realizing the full value of these deals requires comprehensive post-merger integration strategies that address cultural alignment, system compatibility and organisational restructuring. By focusing on harmonizing workplace cultures, streamlining operations and maintaining strategic coherence, pharmaceutical companies can maximize the long-term benefits of mergers and partnerships, ensuring sustainable growth and improved global competitiveness⁴⁰⁻⁴¹.

Green practices:

Incorporating green practices is another cornerstone of SPSCM. This includes adopting eco-friendly packaging materials, optimizing transportation routes to lower carbon emissions and implementing energy-efficient operations in warehouses and distribution centers. Sustainable packaging using biodegradable or recycled materials can significantly reduce environmental waste. Furthermore, establishing return and recycling programs for expired or unused medicines helps minimize pollution and promote responsible waste management. Ethical sourcing is essential to sustainability, ensuring that raw materials and pharmaceutical ingredients are procured responsibly. Companies are increasingly collaborating with suppliers, manufacturers and distributors to reduce energy consumption, minimize waste and comply with environmental and social responsibility standards. Partnerships with regulatory agencies, NGOs and academic institutions promote knowledge exchange, innovation and adherence to sustainability goals. Data analytics serves as a key enabler for proactive and efficient management. By analyzing large datasets, organisations can forecast demand accurately, optimize resource allocation and detect inefficiencies or potential risks within the supply chain⁴²⁻⁴³.

FUTURE DIRECTIONS:

The pharmaceutical supply chain is essential for ensuring that medicines and healthcare products are delivered to patients efficiently and reliably. As global markets evolve with rapid technological progress, changing regulations and shifting consumer demands, there is a growing need to strengthen and optimize these supply networks to improve public health resilience. Future advancements are expected to focus on emerging technologies such as artificial intelligence (AI), blockchain and data analytics, along with sustainability initiatives and strategic collaboration among industry stakeholders. The ongoing digital transformation of the pharmaceutical sector is reshaping how supply chains operate by improving transparency, traceability and responsiveness. Through the use of Internet of Things (IoT) systems, companies can monitor temperature, humidity and other critical parameters in real time, ensuring that medicines maintain their integrity during production, storage and transportation. Likewise, data analytics enables organisations to analyze performance trends, predict demand and streamline inventory management to minimize shortages and waste. Sustainability has also become a central aspect of modern supply chain strategies. Many pharmaceutical firms are adopting environmentally friendly logistics, recyclable packaging and energy-efficient manufacturing practices to reduce their carbon footprint and promote ethical operations. The integration of AI and blockchain provides further opportunities to enhance reliability and trust across the supply chain. AI-driven forecasting tools improve demand prediction and risk analysis, allowing for timely production adjustments and proactive responses to market fluctuations. Blockchain technology ensures data transparency and security,

helping verify product authenticity and prevent counterfeit drugs from entering the market. It also simplifies compliance by offering real-time access to verifiable records that support audits and quality assurance. To fully realize the benefits of digital transformation, continuous innovation and cross-sector collaboration are vital. Partnerships among pharmaceutical companies, academic institutions and technology firms can accelerate research into practical, scalable solutions for complex supply chain challenges. Regulatory authorities should also update compliance frameworks to align with technological advancements while maintaining patient safety and product integrity. In parallel, developing workforce competencies is critical employees need specialized training in digital tools, data analytics and emerging technologies to support smarter, more agile operations. Collaborative data-sharing platforms can enhance coordination between manufacturers, suppliers, distributors and healthcare providers, ensuring that decision-making is transparent and efficient⁴⁴⁻⁴⁸.

2. CONCLUSION

Building a sustainable pharmaceutical supply chain is essential for maintaining uninterrupted access to medicines while minimizing environmental and economic impacts. Integrating technologies such as digital tracking, automation and data analytics promotes transparency and efficiency across all stages of production and distribution. Environmentally responsible sourcing, optimized packaging and green transportation further reduce waste and carbon emissions. Strengthening partnerships with suppliers and local manufacturers enhances resilience against global disruptions, ensuring supply continuity during crises. Moreover, aligning operations with international sustainability frameworks fosters accountability and long-term competitiveness. A forward-looking approach that combines innovation, policy compliance and workforce training can transform the pharmaceutical supply chain into a model of adaptability and sustainability.

ACKNOWLEDGEMENT: NIL

CONFLICT OF INTEREST: NIL

3. REFERENCES

- Christopher, M., & Peck, H. (2004). Building the resilient supply chain. *International Journal of Logistics Management*, 15(2), 1-14. Doi: <https://doi.org/10.1108/09574090410700275>
- Ganguly, A., Chatterjee, D., & Talukdar, A. (2018a). Knowledge sharing barriers affecting pharmaceutical supply chain performance. In Szmelter A. (Ed.) *Global supply chains in the pharmaceutical industry*. IGI Global (Accepted, in press) Doi:
- Ganguly, A., Chatterjee, D., & Rao, H. (2018b). The role of resiliency in managing supply chains disruptions. In Y. Khojasteh (Ed.), *Supply chain risk management: advanced tools, models and developments (237-251)* Singapore: Springer. Doi: https://doi.org/10.1007/978-981-10-4106-8_14
- Ponomarov, S. Y., & Holcomb, M. C. (2009). Understanding the concept of supply chain resilience. *The International Journal of Logistics Management*, 20(1), 124-143. Doi: <https://doi.org/10.1108/09574090910954873>
- Shuai, Y., Wang, X., & Zhao, L. (2011). Research on measuring method of supply chain resilience based on biological cell elasticity theory. In 2011 IEEE International Conference on Industrial Engineering and Engineering Management (IEEM), December 6-9, Singapore, 264-268. Doi: <https://doi.org/10.1109/ieem.2011.6117919>
- Longo, F. and Oren, T. (2008). Supply chain vulnerability and resilience: a state of the art overview. *Proceedings of European Modeling & Simulation Symposium*, edited by Campora S. Giovanni, September 17-19, Italy.
- Tukamuhabwa, B. R., Stevenson, M., Busby, J., & Zorzini, M. (2015). Supply chain resilience: definition, review and theoretical foundations for further study. *International Journal of Production Research*, 53(18), 5592-5623. Doi: <https://doi.org/10.1080/00207543.2015.1037934>
- Anjorin, K. F., Raji, M. A., & Olodo, H. B. (2024). Voice assistants and US consumer behavior: A comprehensive review: investigating the role and influence of voice-activated technologies on shopping habits and brand loyalty. *International Journal of Applied Research in Social Sciences*, 6(5), 861-890
- Ige, A. B., Kupa, E., & Ilori, O. (2024). Best practices in cybersecurity for green building management systems: Protecting sustainable infrastructure from cyber threats. *International Journal of Science and Research Archive*, 12(1), 2960-2977
- Udegbe, F. C., Nwankwo, E. I., Igwama, G. T., & Olaboye, J. A. (2024). Integration of blockchain technology in biomedical diagnostics: Ensuring data security and privacy in infectious disease surveillance. *Engineering Science & Technology Journal*, 3(2), August.
- Oyeniran, C.O., Adewusi, A.O., Adeleke, A. G., Akwawa, L.A., Azubuko, C. F. (2023) AI-driven devops: Leveraging machine learning for automated software development and maintenance. *Engineering Science & Technology Journal*, 4(6), pp. 728-740
- Arowoogun, J. O., Ogugua, J. O., Odilibe, I. P., Onwumere, C., Anyanwu, E. C., & Akomolafe, O. (2024). COVID-19 vaccine distribution: A review of strategies in Africa and the USA
- Soni SJ, Patel AN. Digital transformation and Industry 4.0 in pharma manufacturing: the role of IoT, AI and big data. *Journal of Integral Sciences*. 2024;7(4):1-8. doi:10.37022/jis.v7i4.92
- Shlash Mohammad AA, Khanfar IA, Al Oraini B, Vasudevan A, Mohammad SI, Fei Z. Predictive analytics on artificial intelligence in supply chain optimization. *Data and Metadata*. 2024;3:395. doi:10.56294/dm2024395.
- Hosseini Shekarabi SA, Kiani Mavi R, Romero Macau F. Supply chain resilience: a critical review of risk mitigation, robust optimisation and technological solutions and future research directions. *Global Journal of Flexible Systems Management*. 2025;26:681-735. doi:10.1007/s40171-025-00458-8.
- Lambrechts, W. (2020). Ethical and sustainable sourcing: Toward strategic and holistic sustainable supply chain management. In W. Leal Filho, A. M. Azul, L. Brandli, A. L. Salvia, & T. Wall (Eds.), *Encyclopedia of the UN Sustainable Development Goals: Decent Work and Economic Growth* (pp. 402-414). Springer. https://doi.org/10.1007/978-3-319-71058-7_11-1
- Handfield, R., Finkenstadt, D. J., Schneller, E. S., Godfrey, A. B., & Guinto, P. (2020). A commons for a supply chain in the post-COVID-19 era: The case for a reformed strategic national stockpile. *The Milbank Quarterly*, 98(4), 1058-1090.
- Thazin, M.P. and Sakulbumrungsil, R., 2022. Analysis of pharmaceutical inventory management in a state hospital in Myanmar. *The Thai Journal of Pharmaceutical Sciences*, 46(2), pp.203-207.
- Iyengar, S., Hedman, L., Forte, G., & Hill, S. (2020). Medicine shortages: A commentary on causes and mitigation strategies. *BMC Medicine*, 18(1), 1-10.
- Woodcock, J. (2019). Safeguarding pharmaceutical supply chains in a global economy. *Testimony before the house committee on energy and commerce, subcommittee on health*.
- Tucker, E. L., Daskin, M. S., Sweet, B. V., & Hopp, W. J. (2020). Incentivizing resilient supply chain design to prevent drug shortages: Policy analysis using two- and multi-stage stochastic programs. *IIE Transactions*, 52(4), 394-412.

- Hu, Y. and Ghadimi, P., 2023, June. A Review of Artificial Intelligence Application on Enhancing Resilience of Closed-loop Supply Chain. In 2023 IEEE International Conference on Engineering, Technology and Innovation (ICE/ITMC) (pp. 1-8). IEEE
- Tseng, J. H., Liao, Y. C., Chong, B., & Liao, S. W. (2018). Governance on the drug supply chain via gcoin blockchain. *International Journal of Environmental Research and Public Health*, 15(6), 1055
- Aljohani, A. (2023). Predictive analytics and machine learning for real-time supply chain risk mitigation and agility. *Sustainability*, 15(20), 15088.
- Tien NH, Anh DBH, Thuc TD. Global supply chain and logistics management. 2019.
- Uthayakumar, R., & Priyan, S. (2013). Pharmaceutical supply chain and inventory management strategies: Optimization for a pharmaceutical company and a hospital. *Operations Research for Health Care*, 2(3), 52-64.
- Spinks, J., Mcrae, P., & Young, B. (2016). Improving medicine supply and management in Australia: Can health reform provide a remedy? *Australian Health Review*, 40(6), 644-649
- Mahendran, H., Narasimhan, K., Nagarajan, N., & Gopinath, S. (2011). Investigation of supply chain risk in the Indian pharmaceutical industry: A case study. *International Journal of Economics and Management Engineering*, 5(11), 1701-1705.
- Yu, X., Li, C., Shi, Y., & Yu, M. (2010). Pharmaceutical supply chain in China: Current issues and implications for health system reform. *Health Policy*, 97(1), 8-15
- Rosoff, H., Siko, R., John, R., & Burns, W. J. (2012). Should I stay or should I go? An experimental study of health and economic government policies following a severe biological agent release. *Environment Systems and Decisions*, 32(1), 139-150
- Deshpande AR. Supply chain management dimensions, supply chain performance and organizational performance: an integrated framework. *Int J Bus Manag*. 2012;7:2-19.
- Craighead, C. W., Blackhurst, J., Rungtusanatham, M. J., & Handfield, R. B. (2007). The severity of supply chain disruptions: Design characteristics and mitigation capabilities. *Decision Sciences*, 38(1), 131-156.
- Xu, S., Zhang, X., Feng, L., & Yang, W. (2020). Disruption risks in supply chain management: A literature review based on bibliometric analysis. *International Journal of Production Research*, 58(11), 3508-3526.
- Peck, H. (2005). Drivers of supply chain vulnerability: An integrated framework. *International Journal of Physical Distribution & Logistics Management*, 35(4), 210-232.
- McKinsey & Company. (2023). Supply chain disruption and resilience. Retrieved from <https://www.mckinsey.com/capabilities/operations/our-insights/taking-the-pulse-of-shifting-supply-chains>
- Torabizadeh M, Khatami Rad M, Noshadi A. Effect of information system strategies on supply chain strategies and supply chain performance. *World Acad Sci, Eng Technol*. 2012;61:940-5
- Zhu Q, Krikke H, CaniëlsMC. Integrated supply chain risk management: a systematic review. *Int J Logist Manag*. 2017;28(4):1123-41
- Graves S, Lei L, Melamed B, Pinedo M, Qi L, Shen Z, et al., editors. New challenges to emergency management of pharmaceutical/healthcare supply chain disruptions. DHS Workshop on Incident Management, Resource Management and Supply Chain Management; 2009.
- Valentina De Marchi, Elisa Giuliani, Roberta Rabelotti , Do Global Value Chains Offer Developing Countries Learning and Innovation Opportunities? *The European Journal of Development Research*,30, 389-407 (2018).
- Ab Talib, M. S., & Abdul Hamid, A. B. Application of critical success factors in supply chain management, *International Journal of Supply Chain Management*, 3, 21-29, (2014).
- Alsmadi, M., Almani, A., & Khan, Z. Implementing an integrated ABC and TOC approach to enhance decision making in a Lean context: A case study. *International Journal of Quality & Reliability Management*, 31, 906-920, (2014).
- Anyanwu, E. C., Arowoogun, J. O., Odilibe, I. P., Akomolafe, O., Onwumere, C., & Ogugua, J. O. (2024). The role of biotechnology in healthcare: A review of global trends
- Ogugua, J. O., Anyanwu, E. C., Olorunsogo, T., Maduka, C. P., & Ayo-Farai, O. (2024). Ethics and strategy in vaccination: A review of public health policies and practices. *International Journal of Science and Research Archive*, 11(1), 883-895.
- Technologies: Past, Present and Future Prospects. *International Medical Science Research Journal*, 4(2), 183-193. [192]. Onyekwelu, N.P., Ezeafulukwe, C., Owolabi, O.R., Asuzu, O.F., Bello, B.G., et al. (2024). Ethics and corporate social responsibility in HR: A comprehensive review of policies and practices. *International Journal of Science and Research Archive*, 11(1), pp. 1294- 1303
- Abdul, S., Adeghe, E. P., Adegoke, B. O., Adegoke, A. A., & Udedeh, E. H. (2024). A review of the challenges and opportunities in implementing health informatics in rural healthcare settings. *International Medical Science Research Journal*, 4(5), 606-631.
- Akinsulire, A. A., Idemudia, C., Okwandu, A. C., & Iwuanyanwu, O. (2024). Supply chain management and operational efficiency in affordable housing: An integrated review. *Magna Scientia Advanced Research and Reviews*, 11(2), 105-118
- Ebeh, C. O., Okwandu, A. C., Abdulwaheed, S. A., & Iwuanyanwu, O. (2024). Sustainable project management practices: Tools, techniques and case studies. *International Journal of Engineering Research and Development*, 20(8), 374-381.
- Girish Gupta et al. Strategies for Developing a Future-Ready Pharmaceutical Supply Chain. *IJAIDR*. 2025; 16(2):1-10